Clinical and Immunologic Parameters During Thalidomide Treatment of Lupus Erythematosus
May 2000
in “
International Journal of Dermatology
”
thalidomide lupus erythematosus systemic lupus erythematosus cutaneous lupus erythematosus C-reactive protein autoantibodies to dsDNA complement components C3 complement components C4 immunoglobulin inflammatory skin lesions hair regrowth LE-related alopecia polyneuropathy teratogenic risks alopecia skin lesions
Studysummary This study found that thalidomide increased peripheral lymphocyte counts and reduced inflammation in lupus erythematosus patients, but was associated with polyneuropathy, suggesting careful use in refractory cases.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer